by Administrators Qynapse | Aug 31, 2020 | News
The world has been facing the COVID-19 global pandemic for several months now, yet new symptoms are still being discovered. According to a recent study, 45% of patients with severe manifestations of COVID-19 experience neurological damage and neurological symptoms...
by Administrators Qynapse | Aug 6, 2020 | News
QyScore®, the FDA-cleared and CE-marked software commercialized by Qynapse, confirms its value for the rapid measurement of brain atrophy and white matter hyperintensity in a clinical routine setting. The validation study compared the performance of QyScore® with...
by Administrators Qynapse | Jul 23, 2020 | News
The Alzheimer’s Association International Conference® (AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. This year’s event takes place virtually, an exciting new way of sharing research discoveries and have...
by Administrators Qynapse | Feb 3, 2020 | News
QyScore® allows automated quantification of a broad portfolio of Magnetic Resonance Imaging markers that are key to support early diagnosis and clinical monitoring of neurodegenerative disorders PARIS, France, Feb 3. 2020 — QYNAPSE, a medical technology company,...
by Administrators Qynapse | Jul 1, 2019 | News
From July 14 – 18th, Qynapse will be part of the 2019 Alzheimer’s Association International Conference (AAIC®) held in Los Angeles, California. For the second time, Qynapse will present at the AAI Conference – the largest global forum to advance dementia science. The...
by Administrators Qynapse | Apr 11, 2019 | News
QyScore®, the software by Qynapse that provides automated volumetric measurements of brain structures, takes a big step forward with the validation of performance for one of its major functionalities. The validation study (conducted in 2018) focuses on the performance...
